Back

Efficacy and safety of treprostinil in pulmonary arterial hypertension: a meta-analysis of randomized trials

30 August 2026 (17:12 - 17:24)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy of pulmonary arterial hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Mohammad Azeem Malik

Lahore, Punjab (Pakistan)

4 More presentations in this session

Presentation thumbnail
Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: the DAPAH randomized controlled trial
Doctor M. Ersboll (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Quick and sustained right ventricular reverse remodeling at early, mid and late follow-Up under sotatercept
Doctor M. EL BLIDI (Le Kremlin-Bicetre, FR)
Abstract Slides
Presentation thumbnail
Impact of targeted therapies withPDE5 inhibitors, endothelin receptor antagonists and sotatercept on functional tricuspid regurgitation in pulmonary arterial hypertension
Mr J. Gentz (Cologne, DE)
Abstract Slides
Presentation thumbnail
Early therapy failure in incident pulmonary arterial hypertension
Doctor G. Savonitto (Stockholm, SE)
Abstract Slides

Access the full session

Session thumbnail
Pharmacotherapy of pulmonary arterial hypertension
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 17:12 CET
You may be interested in
thumbnail
Congress Presentation
Real-life evidence of the use of subcutaneous treprostinil in pulmonary hypertension in Argentina
1 July 2021
thumbnail
Congress Presentation
Cardiovascular mechanisms of exercise intolerance in individuals with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis
25 April 2024
thumbnail
Congress Presentation
A systematic review and meta-analysis of health-related quality of life (HRQoL) outcomes in randomised controlled trials for pulmonary arterial hypertension (PAH)
1 September 2024
thumbnail
Congress Presentation
Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension
31 August 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources